Femoxetine (INN; tentative brand name Malexil; developmental code name FG-4963) is a drug related to paroxetine that was being developed as an antidepressant by Danish pharmaceutical company Ferrosan in 1975 before acquisition of the company by Novo Nordisk.

Development was halted to focus attention on paroxetine instead, as femoxetine could not be administered as a daily pill.

Jørgen Anders Christensen's name is on the patents[1][2] and Jorgen Buus-Lassen's name is on the pharmacology paper.

[4] In a separate patent, Ferrosan stated that Femoxetine could be used as an appetite suppressant,[5] using ten times the dosage than for paroxetine, 300 - 400mg daily.

Femoxetine has the same stereochemical properties as Nocaine, another agent with a similar structure claimed to have been synthesized using arecoline as the starting alkaloid.